What Is Klow 80mg?

Overview

KLOW is a four-peptide blend developed in research-supply settings that combines three regenerative peptides — GHK-Cu (50 mg), BPC-157 (10 mg), and TB-500 (10 mg), collectively known as the "GLOW" stack — with the α-MSH(11–13) tripeptide KPV (10 mg). Researchers select the four-peptide format to investigate whether complementary mechanisms — copper-dependent extracellular-matrix synthesis, angiogenic and cytoprotective signaling, actin/cytoskeletal remodeling, and direct NF-κB suppression — produce additive or synergistic outcomes in models of tissue injury and inflammation that no single component covers alone.

The pharmacological logic of the stack distributes work across four compartments. GHK-Cu functions as a copper-delivery vehicle and broad gene modulator — Pickart's group has reported >50% expression changes in roughly 31% of the human genome, with ECM synthesis (collagen I/III, elastin, decorin, glycosaminoglycans) and antioxidant pathways (Nrf2/HO-1, ferritin iron blockade) prominently activated.[1][2] BPC-157 contributes a separate axis: VEGFR2-dependent angiogenesis, FAK-paxillin and Src-Caveolin-1/eNOS modulation, and broad cytoprotective coverage across gut, tendon, ligament, and CNS preclinical models.[3][6] TB-500 (Ac-LKKTETQ) is the actin-binding fragment of Thymosin β4 and is investigated for cytoskeletal G-actin sequestration, cell migration, and re-epithelialization.[7][8]

KPV is the layer that distinguishes KLOW from GLOW. Unlike its parent α-MSH, KPV does not bind melanocortin receptors; it enters cells via the PepT1 (SLC15A1) oligopeptide transporter, binds Importin-α3, and blocks nuclear translocation of NF-κB p65 while stabilizing IκBα — producing a direct intracellular suppression of inflammatory transcription at concentrations as low as 10 nM.[4][9] Layered onto the regenerative trio, KPV is positioned in research designs as the dedicated cytokine-quenching component, complementing GHK-Cu's NF-κB/p38-MAPK modulation and BPC-157's NO-system buffering. The four peptides are supplied co-lyophilized in a single 80 mg vial; no large-scale randomized human trial has been conducted on the blend itself, and all available data are from in-vitro and animal studies of the individual components.